YongJin Kim

7PUBLICATIONS
23CO-AUTHORS
Molecular targetsMajor global burdens of diseaseNeurology and neuromuscular diseasesDisease surveillanceCancer therapy (excl. chemotherapy and radiation therapy)
Featured researcher

Get your video featured.

JoVEPublish with JoVE
Journal

Publications (7)

|May 29, 2025
Economic Burden and Provider Referral Patterns Among Patients with Unresectable Stage III EGFR-Mutated NSCLC Receiving Chemoradiotherapy in the United States.

YongJin Kim, Yong Zhu, Kristin J Moore

|Oct 24, 2024
Disease Overlap, Healthcare Resource Utilization, and Costs in Patients with Eosinophilic Granulomatosis with Polyangiitis: A REVEAL Sub-study.

Xiao Xu, Christopher Edmonds, YongJin Kim

|Feb 26, 2024
Patient characteristics, treatment patterns, healthcare resource utilization, and costs among patients diagnosed with neurofibromatosis type 1 with and without plexiform neurofibromas in Japan.

Yuichi Yoshida, Keiichi Tozawa, Ryo Koto

|Oct 12, 2023
Real-World Investigation of Eosinophilic-Associated Disease Overlap (REVEAL): Analysis of a US Claims Database.

Anamaria Brailean, Justin Kwiatek, Danuta Kielar

|Mar 31, 2021
Cost-Effectiveness Analysis of Afatinib, Erlotinib, and Gefitinib as First-Line Treatments for EGFR Mutation-Positive Non-Small-Cell Lung Cancer in Ontario, Canada.

Yong-Jin Kim, Mark Oremus, Helen H Chen

|Feb 05, 2021
Factors affecting treatment selection and overall survival for first-line EGFR-tyrosine kinase inhibitor therapy in non-small-cell lung cancer.

Yong-Jin Kim, Mark Oremus, Helen H Chen

Pageof 2

Frequent Collaborators

3 joint publications

Susan Horton

3 joint publications

Mark Oremus

3 joint publications

Helen H Chen

3 joint publications

Thomas McFarlane